Advanced to first-line RAS-mutated metastatic colorectal cancer (mCRC) for lead program based on positive clinical and preclinical data and guidance from FDA.

Expanded relationship with Pfizer, which will provide clinical execution of new Phase 2 randomized first-line mCRC trial of onvansertib + standard-of-care (SoC) versus SoC, with interim topline data expected in mid-2024.

Advanced to first-line mPDAC with plan to initiate new Phase 2 investigator-initiated trial of onvansertib + SoC.

Onvansertib monotherapy demonstrated single agent activity in Phase 2 investigator-initiated trial in refractory patients with extensive stage small cell lung cancer.